系统免疫炎症指数对小细胞肺癌患者预后的影响

Effect of systemic immune-inflammation index on prognosis of patients with small cell lung cancer

目的探讨治疗前以中性粒细胞、血小板、淋巴细胞为基础的系统免疫炎症指数(systemic immune-inflammation index,SII)对小细胞肺癌(small cell lung cancer,SCLC)患者临床预后的影响。方法回顾性分析SCLC患者98例的临床资料。根据治疗前血常规结果计算出SII值,通过受试者工作特征曲线得出SII的最佳截断值。采用Kaplan-Meier曲线和Cox风险比例回归模型估计SII水平和各临床病理特征对患者无进展生存期(progression free survival,PFS)和总生存时间(overall survival,OS)的影响。结果SII的最佳截断值为571.5;低SII组临床分期中局限期的比例高于高SII组(P<0.05);低SII组的中位PFS和中位OS均好于高SII组(P<0.001)。多因素分析进一步显示,治疗前SII水平是SCLC患者PFS和OS的独立预后因素(P<0.05)。结论治疗前高SII水平SCLC患者往往提示预后较差,对于判断预后具有重要意义。

Objective To investigate the effect of systemic immune-inflammation index(SII)based on neutrophil,platelet and lymphocyte on the clinical prognosis of patients with small cell lung cancer(SCLC).Methods The case data of 98 patients with SCLC were analyzed retrospectively.According to the results of blood routine before treatment,the SII value was calculated,and the optimal cut-off value of SII was obtained by ROC curve.The effects of SII level and clinicopathological characteristics on progression-free survival(PFS)and the overall survival(OS)were estimated using the Kaplan-Meier curves and Cox proportional hazards regression models.Results The optimal cut-off value of SII was 571.5.The proportion of the low SII group in the limited stage was higher than that of the high SII group(P<0.05).The median PFS and OS of the low SII group were longer than that of the high SII group(P<0.001).Multivariate analyses further revealed SII level as an independent prognostic factor for PFS and OS(P<0.05).Conclusion High SII often indicates poor prognosis and plays an important role in prognostic evaluation of SCLC patients.